European Commission extends Orkambi marketing authorization to children aged 6-11 years Jan. 10, 2018
GenSight cleared by MHRA to begin phase I/II study of GS-030 gene therapy for retinitis pigmentosa Jan. 10, 2018
Molecular Partners reports initial data from phase II study of MP-0250 in multiple myeloma Jan. 10, 2018
Global Blood Therapeutics' voxelotor given breakthrough therapy designation for sickle cell disease Jan. 10, 2018
RSS